查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856989

全球精准益生菌市场：预测至2032年－按产品类型、剂型、通路、应用、最终用户和地区分類的分析

Precision Probiotics Market Forecasts to 2032 - Global Analysis By Product Type, Form, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球精准益生菌市场预计到 2025 年将达到 18.5 亿美元，到 2032 年将达到 20.8 亿美元，预测期内复合年增长率为 1.7%。

精准益生菌是根据个人的健康状况、基因组成和微生物组组成，选择和配製的特定微生物菌株。与普通益生菌不同，精准益生菌旨在满足特定的生理需求，从而带来个人化的治疗益处，例如改善肠道健康、调节免疫功能和支持代谢。这些菌株通常透过基因组和临床数据进行检验，从而提高疗效和可预测性。精准益生菌代表着机能性食品、膳食补充剂和临床应用中，营养和微生物干预向个人化方向发展的趋势。

根据《微生物学前沿》（2025 年）的报导，“益生菌已被证明能显着降低抗生素相关腹泻的发生率，有效率在 42% 到 57% 之间，具体取决于菌株和剂量。”

消费者越来越需要针对微生物的解决方案。

元基因组和人工智慧驱动的诊断技术的进步使得益生菌推荐更加精准。这些创新正在推动人们从非专利补充剂转向标靶治疗，尤其是在治疗肠躁症、肥胖症和情绪障碍等慢性疾病方面。数位健康平台与微生物组科学的融合进一步加速了益生菌在健康和临床领域的应用。随着人们对微生物组在免疫、消化和心理健康方面作用的认识不断提高，人们开始寻求针对自身独特健康状况的、具有特定菌株的配方。

复杂的科学论点会让消费者感到困惑。

许多消费者难以区分普通益生菌和精准菌株，导致困惑和怀疑。缺乏标准化的标籤和不同人群中不一致的临床结果进一步加剧了购买决策的复杂性。此外，严格的菌株验证和监管合规要求也增加了研发时间和成本。这些障碍可能会阻碍益生菌产品进入大众市场，尤其是在健康素养较低和监管强度较弱的地区。

拓展至心理健康与代谢健康领域

对肠脑轴和微生物对神经传导物质影响的研究正在开闢新的治疗途径。一些公司正在研发针对焦虑、睡眠和认知功能的配方，并通常结合数位追踪工具。同样，针对体重管理、胰岛素敏感性和血脂谱的代谢健康解决方案也不断出现。这些创新得益于人们对非药物干预和预防性护理日益增长的需求，尤其是在老化和健康意识增强的人群中。

科学怀疑论和不一致的结果

儘管某些菌株在对照试验中展现出令人鼓舞的结果，但它们在实际应用中并未一致地有效。这种差异性可能会引发医疗服务提供者和监管机构的质疑，从而延缓产品核可和报销流程。此外，大量检验的益生菌产品和夸大其词的标语也会削弱消费者的信任。缺乏可靠的数据和透明的沟通，精准益生菌可能会面临声誉方面的挑战，进而影响其发展。

新冠疫情的影响：

疫情提升了全球对免疫卫生的关注度，也增加了对微生物组干预的需求。针对呼吸系统韧性和全身免疫力的精准益生菌产品备受青睐。同时，远距离诊断和居家微生物组检测的兴起，让消费者无需前往诊所即可探索个人化的肠道健康解决方案。供应链中断最初影响了原材料的可得性，但数位化平台和订阅模式有助于维持用户参与。

预计在预测期内，腰痛治疗领域将成为最大的细分市场。

由于其临床有效性和监管支持，预计在预测期内，脂质体结合蛋白（LBP）疗法将占据最大的市场份额。这些製剂旨在针对特定疾病进行干预，并通常有可靠的临床试验和FDA审批途径作为支撑。目前，LBP正被探索用于治疗溃疡性大肠炎、泛自闭症障碍和代谢症候群等疾病。 LBP在细胞层面调节宿主-微生物组相互作用的能力使其成为下一代疗法。生物技术公司和製药公司之间的策略伙伴关係正在进一步推动创新和商业化。

预计在预测期内，消化器官系统健康细分市场将以最高的复合年增长率成长。

预计在预测期内，消化器官系统健康领域将呈现最高的成长率，这主要得益于消化器官系统疾病和生活方式相关的肠道菌丛失衡盛行率的上升。针对腹胀、肠躁症 (IBS) 和肠道菌丛失调的精准益生菌产品正日益受到消费者和临床医生的青睐。这些产品通常包含多种菌株的混合物，并采用标靶递送机制以确保疗效。消费者意识的提高、诊断工具的改进以及与饮食干预的结合，都为该领域带来了积极影响。封装和缓释技术的创新正在提高菌株的存活率和治疗效果。

比最大的地区

由于北美拥有先进的医疗基础设施、较高的消费者健康意识和强大的研发能力，预计在预测期内将占据最大的市场份额。该地区汇集了多家领先的微生物组研究机构和新兴企业正在推动创新和产品核可。此外，人口老化对个人化健康和预防性医疗保健的需求日益增长，也促进了市场扩张。主要公司的策略投资和收购正在巩固北美在该领域的领先地位。

复合年增长率最高的地区：

预计亚太地区在预测期内将呈现最高的复合年增长率，这主要得益于医疗保健投资的增长、中等收入阶层的壮大以及人们对功能性营养日益增长的兴趣。中国、印度和日本等国家正经历微生物组研究和肠道健康解决方案的消费者需求激增。政府推行的预防医学和数位健康倡议正在加速这些技术的普及应用。此外，该地区多样化的微生物组组成也为靶向益生菌的开发提供了独特的机会。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 产品分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

第五章 全球精准益生菌市场（依产品类型划分）

  • 治疗性腰痛
  • 非处方（OTC）精准营养补充剂
  • 个人化、直接面向消费者的益生菌
  • 伴随诊断、微生物组检测
  • 其他产品类型

6. 全球精准益生菌市场（依形式划分）

  • 药片
  • 药片
  • 粉末
  • 液体
  • 软糖
  • 其他格式

7. 全球精准益生菌市场（依分销通路划分）

  • 网路商店
  • 药房和药品商店
  • 超级市场和大卖场
  • 专卖店
  • 其他分销管道

8. 全球精准益生菌市场（依应用划分）

  • 消化器官系统健康
  • 免疫健康
  • 代谢健康
  • 心理表现
  • 体重管理
  • 皮肤健康
  • 营养优化
  • 其他用途

9. 全球精准益生菌市场（以最终用户划分）

  • 医院和诊所
  • 研究机构/合约研究组织
  • 製药和生物技术公司
  • 营养补充品和机能性食品公司
  • 动物用药品公司
  • 其他最终用户

第十章 全球精准益生菌市场（依地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • Nestle Health Science
  • Danone SA
  • Yakult Honsha Co., Ltd.
  • PepsiCo Inc.
  • Lifeway Foods Inc.
  • Chr. Hansen Holding A/S
  • DuPont Nutrition & Biosciences（IFF）
  • BioGaia AB
  • Probi AB
  • ADM（Archer Daniels Midland）
  • Novozymes A/S
  • Seed Health Inc.
  • ZBiotics Company
  • Amare Global
  • Pendulum Therapeutics
  • Evolve BioSystems
  • UAS Laboratories
  • Cargill Inc.
  • DSM Nutritional Products
  • Kerry Group plc
Product Code: SMRC31854

According to Stratistics MRC, the Global Precision Probiotics Market is accounted for $1.85 billion in 2025 and is expected to reach $2.08 billion by 2032 growing at a CAGR of 1.7% during the forecast period. Precision probiotics are targeted microbial strains selected and formulated based on individual health profiles, genetic makeup, and microbiome composition. Unlike general probiotics, they aim to deliver personalized therapeutic benefits such as improved gut health, immune modulation, or metabolic support by addressing specific physiological needs. These strains are often validated through genomic and clinical data, enhancing efficacy and predictability. Precision probiotics represent a shift toward customized nutrition and microbiome-based interventions in functional foods, supplements, and clinical applications.

According to Frontiers in Microbiology (2025), "Probiotics have shown a significant reduction in the incidence of antibiotic-associated diarrhea, with efficacy rates ranging from 42% to 57% depending on the strain and dosage used"

Market Dynamics:

Driver:

Consumers increasingly seek microbiome-targeted solutions

Advances in metagenomic sequencing and AI-driven diagnostics are enabling more accurate probiotic recommendations. These innovations are fostering a shift from generic supplements to targeted therapeutics, especially in chronic conditions like IBS, obesity, and mood disorders. The convergence of digital health platforms and microbiome science is further accelerating adoption across wellness and clinical segments. With increasing awareness of the microbiome's role in immunity, digestion, and mental wellness, individuals are seeking strain-specific formulations tailored to their unique health profiles.

Restraint:

Complex scientific claims may confuse consumers

Many consumers struggle to differentiate between general probiotics and precision strains, leading to confusion and skepticism. The lack of standardized labeling and inconsistent clinical outcomes across populations further complicate purchasing decisions. Additionally, the need for rigorous strain validation and regulatory compliance increases development timelines and costs. These barriers may hinder mass-market penetration, especially in regions with limited health literacy or regulatory oversight.

Opportunity:

Expansion into mental wellness and metabolic health

Research into the gut-brain axis and microbial influence on neurotransmitters is opening new therapeutic avenues. Companies are developing formulations targeting anxiety, sleep, and cognitive performance, often bundled with digital tracking tools. Similarly, metabolic health solutions are being tailored for weight management, insulin sensitivity, and lipid profiles. These innovations are supported by growing demand for non-pharmaceutical interventions and preventive care, especially among aging and health-conscious populations.

Threat:

Scientific skepticism and inconsistent results

While some strains show promise in controlled trials, replication in real-world settings remains inconsistent. This variability fuels skepticism among healthcare providers and regulators, potentially slowing product approvals and reimbursement pathways. Moreover, the influx of unverified probiotic products and exaggerated marketing claims may erode consumer trust. Without robust data and transparent communication, precision probiotics could face reputational challenges that impact growth.

Covid-19 Impact:

The pandemic heightened global awareness of immune health, prompting increased demand for microbiome-supportive interventions. Precision probiotics targeting respiratory resilience and systemic immunity saw a surge in interest. Simultaneously, the rise of remote diagnostics and at-home microbiome testing enabled consumers to explore personalized gut health solutions without clinical visits. Supply chain disruptions initially affected raw material availability, but digital platforms and subscription models helped sustain engagement.

The therapeutic LBPs segment is expected to be the largest during the forecast period

The therapeutic LBPs segment is expected to account for the largest market share during the forecast period due to their clinical relevance and regulatory traction. These formulations are designed for targeted disease intervention, often supported by robust clinical trials and FDA pathways. LBPs are being explored for conditions such as ulcerative colitis, autism spectrum disorders, and metabolic syndromes. Their ability to modulate host-microbiome interactions at a cellular level positions them as next-generation therapeutics. Strategic partnerships between biotech firms and pharmaceutical companies are further driving innovation and commercialization.

The digestive health segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the digestive health segment is predicted to witness the highest growth rate fueled by rising prevalence of gastrointestinal disorders and lifestyle-related gut imbalances. Precision probiotics targeting bloating, IBS, and dysbiosis are gaining popularity among both consumers and clinicians. These products often incorporate multi-strain blends with targeted delivery mechanisms to ensure efficacy. The segment benefits from increasing consumer awareness, improved diagnostic tools, and integration with dietary interventions. Innovations in encapsulation and time-release technologies are enhancing strain viability and therapeutic outcomes.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to advanced healthcare infrastructure, high consumer awareness, and strong R&D capabilities. The region hosts several leading microbiome research institutions and biotech startups focused on precision probiotics. Regulatory clarity from agencies like the FDA supports innovation and product approvals. Additionally, rising demand for personalized wellness and preventive care among aging populations is fueling market expansion. Strategic investments and acquisitions by major players are consolidating North America's leadership in this domain.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR supported by growing healthcare investments, expanding middle-class populations, and increasing interest in functional nutrition. Countries like China, India, and Japan are experiencing a surge in microbiome research and consumer demand for gut health solutions. Government initiatives promoting preventive care and digital health are accelerating adoption. The region's diverse microbiome profiles also offer unique opportunities for targeted probiotic development.

Key players in the market

Some of the key players in Precision Probiotics Market include Nestle Health Science, Danone S.A., Yakult Honsha Co., Ltd., PepsiCo Inc., Lifeway Foods Inc., Chr. Hansen Holding A/S, DuPont Nutrition & Biosciences (IFF), BioGaia AB, Probi AB, ADM (Archer Daniels Midland), Novozymes A/S, Seed Health Inc., ZBiotics Company, Amare Global, Pendulum Therapeutics, Evolve BioSystems, UAS Laboratories, Cargill Inc., DSM Nutritional Products, and Kerry Group plc.

Key Developments:

In September 2025, Lifeway Foods Inc. Signed Cooperation Agreement with Danone North America for board refreshment, includes governance changes and litigation stay to enhance shareholder value.

In August 2025, Chr. Hansen Holding A/S Launched 2025 Strategy to focus on microbial platforms and fermented plant bases, aims to become a differentiated bioscience leader in food and health.

In June 2025, Nestle Health Science Launched BOOST(R) Advanced Nutritional Shake for adults on GLP-1 weight loss journeys. Supports nutritional needs with high protein and fiber, tailored for metabolic health.

Product Types Covered:

  • Therapeutic LBPs
  • Over-the-Counter (OTC) Precision Supplements
  • Personalized, DTC-Formulated Probiotics
  • Companion Diagnostics & Microbiome Tests
  • Other Product Types

Forms Covered:

  • Capsules
  • Tablets
  • Powders
  • Liquids
  • Gummies
  • Other Forms

Distribution Channels Covered:

  • Online Stores
  • Pharmacies & Drug Stores
  • Supermarkets &Hypermarkets
  • Specialty Stores
  • Other Distribution Channels

Applications Covered:

  • Digestive Health
  • Immune Health
  • Metabolic Health
  • Mental Performance
  • Weight Management
  • Skin Health
  • Nutrition Optimization
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes & CROs
  • Pharmaceutical & Biotech Companies
  • Nutraceutical & Functional Food Companies
  • Animal Health Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Precision Probiotics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Therapeutic LBPs
  • 5.3 Over-the-Counter (OTC) Precision Supplements
  • 5.4 Personalized, DTC-Formulated Probiotics
  • 5.5 Companion Diagnostics & Microbiome Tests
  • 5.6 Other Product Types

6 Global Precision Probiotics Market, By Form

  • 6.1 Introduction
  • 6.2 Capsules
  • 6.3 Tablets
  • 6.4 Powders
  • 6.5 Liquids
  • 6.6 Gummies
  • 6.7 Other Forms

7 Global Precision Probiotics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online Stores
  • 7.3 Pharmacies & Drug Stores
  • 7.4 Supermarkets &Hypermarkets
  • 7.5 Specialty Stores
  • 7.6 Other Distribution Channels

8 Global Precision Probiotics Market, By Application

  • 8.1 Introduction
  • 8.2 Digestive Health
  • 8.3 Immune Health
  • 8.4 Metabolic Health
  • 8.5 Mental Performance
  • 8.6 Weight Management
  • 8.7 Skin Health
  • 8.8 Nutrition Optimization
  • 8.9 Other Applications

9 Global Precision Probiotics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research Institutes & CROs
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Nutraceutical & Functional Food Companies
  • 9.6 Animal Health Companies
  • 9.7 Other End Users

10 Global Precision Probiotics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Nestle Health Science
  • 12.2 Danone S.A.
  • 12.3 Yakult Honsha Co., Ltd.
  • 12.4 PepsiCo Inc.
  • 12.5 Lifeway Foods Inc.
  • 12.6 Chr. Hansen Holding A/S
  • 12.7 DuPont Nutrition & Biosciences (IFF)
  • 12.8 BioGaia AB
  • 12.9 Probi AB
  • 12.10 ADM (Archer Daniels Midland)
  • 12.11 Novozymes A/S
  • 12.12 Seed Health Inc.
  • 12.13 ZBiotics Company
  • 12.14 Amare Global
  • 12.15 Pendulum Therapeutics
  • 12.16 Evolve BioSystems
  • 12.17 UAS Laboratories
  • 12.18 Cargill Inc.
  • 12.19 DSM Nutritional Products
  • 12.20 Kerry Group plc

List of Tables

  • Table 1 Global Precision Probiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Precision Probiotics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Precision Probiotics Market Outlook, By Therapeutic LBPs (2024-2032) ($MN)
  • Table 4 Global Precision Probiotics Market Outlook, By Over-the-Counter (OTC) Precision Supplements (2024-2032) ($MN)
  • Table 5 Global Precision Probiotics Market Outlook, By Personalized, DTC-Formulated Probiotics (2024-2032) ($MN)
  • Table 6 Global Precision Probiotics Market Outlook, By Companion Diagnostics & Microbiome Tests (2024-2032) ($MN)
  • Table 7 Global Precision Probiotics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 8 Global Precision Probiotics Market Outlook, By Form (2024-2032) ($MN)
  • Table 9 Global Precision Probiotics Market Outlook, By Capsules (2024-2032) ($MN)
  • Table 10 Global Precision Probiotics Market Outlook, By Tablets (2024-2032) ($MN)
  • Table 11 Global Precision Probiotics Market Outlook, By Powders (2024-2032) ($MN)
  • Table 12 Global Precision Probiotics Market Outlook, By Liquids (2024-2032) ($MN)
  • Table 13 Global Precision Probiotics Market Outlook, By Gummies (2024-2032) ($MN)
  • Table 14 Global Precision Probiotics Market Outlook, By Other Forms (2024-2032) ($MN)
  • Table 15 Global Precision Probiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global Precision Probiotics Market Outlook, By Online Stores (2024-2032) ($MN)
  • Table 17 Global Precision Probiotics Market Outlook, By Pharmacies & Drug Stores (2024-2032) ($MN)
  • Table 18 Global Precision Probiotics Market Outlook, By Supermarkets &Hypermarkets (2024-2032) ($MN)
  • Table 19 Global Precision Probiotics Market Outlook, By Specialty Stores (2024-2032) ($MN)
  • Table 20 Global Precision Probiotics Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 21 Global Precision Probiotics Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Precision Probiotics Market Outlook, By Digestive Health (2024-2032) ($MN)
  • Table 23 Global Precision Probiotics Market Outlook, By Immune Health (2024-2032) ($MN)
  • Table 24 Global Precision Probiotics Market Outlook, By Metabolic Health (2024-2032) ($MN)
  • Table 25 Global Precision Probiotics Market Outlook, By Mental Performance (2024-2032) ($MN)
  • Table 26 Global Precision Probiotics Market Outlook, By Weight Management (2024-2032) ($MN)
  • Table 27 Global Precision Probiotics Market Outlook, By Skin Health (2024-2032) ($MN)
  • Table 28 Global Precision Probiotics Market Outlook, By Nutrition Optimization (2024-2032) ($MN)
  • Table 29 Global Precision Probiotics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Precision Probiotics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Precision Probiotics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Precision Probiotics Market Outlook, By Research Institutes & CROs (2024-2032) ($MN)
  • Table 33 Global Precision Probiotics Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 34 Global Precision Probiotics Market Outlook, By Nutraceutical & Functional Food Companies (2024-2032) ($MN)
  • Table 35 Global Precision Probiotics Market Outlook, By Animal Health Companies (2024-2032) ($MN)
  • Table 36 Global Precision Probiotics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.